A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge by Ali, Ziad El et al.
216
OPIS PRZYPADKU/CASE REPORT
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 60; Numer Number 3/2009
ISSN 0423–104X
Ziad El Ali M.D., Department of Internal Disease, Metabolic Disorders and Dietetics, University of Medical Sciences,
Przybyszewskiego St. 49, 60–355 Poznan, Poland, tel.: +48 61 869 13 14, faks: +48 61 869 13 14, e-mail: zio73@poczta.fm
A jejunal stromal tumour in a patient with metastatic
neuroendocrine cancer of unknown origin;
a rare coexistence, diagnostic and therapeutic challenge
Guz stromalny jelita cienkiego u pacjentki z przerzutowym rakiem
neuroendokrynnym o nieznanym ognisku pierwotnym;
rzadkie współistnienie, diagnostyczne i terapeutyczne wyzwanie
Ziad El Ali1, Katarzyna Iwanik2, Jerzy Sowiński3, Ewelina Swora1, Marian Grzymislawski1
1Department of Internal Diseases, Metabolic Disorders and Dietetics, University of Medical Sciences, Poznan
2Department of Pathology, University of Medical Sciences, Poznan
3Department of Endocrinology and Metabolism, University of Medical Sciences, Poznan
Abstract
A 59-year-old woman presented to the Department of Gastroenterology complaining of progressing weight loss, unexplained diarrhoea,
and, as revealed by abdominal ultrasound, numerous hyperechogenic foci in the liver. The immunohistochemical evaluations of the
specimens from biopsy revealed well-differentiated hepatic neuroendocrine metastases. The biochemical marker levels, including serum
chromogranin A (CGA) and urine 5-hydroxyindolacetic acid (5-HIAA) 24-hour excretion, were significantly elevated. Whole body somato-
statin receptor scintigraphy showed tracer accumulation in the liver lesions, with no extrahepatic tumour, possibly the primary origin.
Long-term somatostatin analog therapy was initiated and a peptide-receptor targeted radionuclide therapy decision was made parallel to
this treatment. Therefore, a followed-up CT scan of the abdomen showed, as well as the metastatic changes within the liver, a well-
vascularised jejunal tumour suspected to be the primary focus of the disseminated neuroendocrine neoplasm. Unexpectedly, the patholo-
gical examination revealed a positive cell reaction for CD 117, confirming the diagnosis of a rare jejunal stromal tumour. Two months later
peptide-receptor therapy with 90Y/77Lu-DOTA-TATE was commenced. (Pol J Endocrinol 2009; 60 (3): 216–220)
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Streszczenie
Pacjentkę 59-letnią przyjęto do Kliniki Gastroenterologii z powodu postępującego spadku masy ciała, biegunki o niewyjaśnionej etiologii,
oraz wykrytych w badaniu ultrasonograficznym licznych ognisk hyperechogenicznych w wątrobie. Wykonano celowaną biopsją cienko-
igłową i rozpoznano zmiany przerzutowe o utkaniu neuroendokrynnym o wysokim stopniu zróżnicowania (cytologia + immunohisto-
chemia). Badania biochemiczne wykazały podwyższone stężenie chromogranin A (CGA) w surowicy krwi i zwiększone wydalanie kwasu
5-hydroksyindolooctowego (5-HIAA) w dobowej zbiórce moczu. Scyntygrafia receptorowa ujawniła dodatnią ekspresję receptorów so-
matostatynowych w obrębie zmian w wątrobie, natomiast nie znaleziono żadnego pozawątrobowego patologicznego ogniska gromadze-
nia znacznika mogącego odpowiadać pierwotnemu guzowi neuroendokrynnemu. Rozpoczęto leczenie objawowe długodziałającym ana-
logiem somatostatyny i równolegle do tego podjęto decyzję o zakwalifikowaniu pacjentki do celowanej peptydowej receptorowej terapii
radioizotopowej. W tym celu wykonano kontrolne badanie tomografii komputerowej jamy brzusznej, które oprócz zmian w wątrobie, wyka-
zało nieopisanego wcześniej dobrze unaczynionego guza w jelicie cienkim (pierwotny guz neuroendokrynny?). Pacjentkę skierowano do
leczenia operacyjnego. Ku zaskoczeniu autorów pracy badanie histopatologiczne wykazało dodatnią ekspresję CD117 potwierdzającą roz-
poznanie rzadkiego guza stromalnego jelita cienkiego. Dwa miesiące później rozpoczęto peptydową receptorową terapię radioizotopową
z użyciem 90Y/77Lu-DOTA-TATE. Pacjentka otrzymała dwie dawki tego leku, obecnie jest stabilna, zaplanowano dalsze leczenie.
(Endokrynol Pol 2009; 60 (3): 216–220)
Słowa kluczowe: rozsiany guz neuroendokrynny o nieznanym ognisku pierwotnym, GIST jelita cienkiego, współistnienie
Introduction
Neuroendocrine tumours (NET) represent a rare, hete-
rogenous, slowly growing group of neoplasms. NETs
are classified according to classical structural criteria
combined with proliferation index Ki67 into well diffe-
rentiated endocrine tumours (Ki67 < 2%), well diffe-
rentiated endocrine carcinoma (Ki67 > 2% but < 15%),
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poorly differentiated endocrine carcinoma (> 15%), and
mixed exocrine-endocrine tumours [1, 2]. Previous stu-
dies showed that approximately 20% of patients with
NETs develop other cancers, one third of which arise
in the gastrointestinal tract [3].
Stromal tumours of the gastrointestinal tract (GIST)
are rare neoplasms that account for < 1% of all gastro-
intestinal malignancies. Most GISTs (95%) are immu-
nohistochemically positive for c-kit protein (CD 117)
and CD 34 [4–6]. The percentage of patients with GIST,
in whom other neoplasms may be diagnosed, ranges
between 2.95% and 33.3%. The most common secon-
dary tumours are colorectal cancer, prostate cancer,
pancreatic cancer, and neoplasms derived from lym-
phoid tissue [7].
 The coexistence of a second different neoplasm in a
patient with metastatic disseminated neuroendocrine
tumour creates a unique challenge and has particular
importance in the prognosis and therapeutic approach
to the management of both neoplasms.
Case report
A 59-year-old female was referred to the Gastroentero-
logical Outpatient Clinic in September 2005 due to loss
of weight and diarrhoea. An interview revealed that the
disturbances started about 4 months earlier with a gra-
dual weight loss despite good appetite. Two months
later diarrhoea developed (up to 6 times a day), the sto-
ol was loose with no blood. There were no typical symp-
toms for carcinoid tumour, namely: abdominal pain,
flushes, blood pressure drop, or signs of right heart fa-
ilure. Ultrasonography of the abdomen showed nume-
rous hyperechogenic strongly suspected to be metasta-
tic foci in the liver. Consequently, the patient was refer-
red to the Gastroenterology Department of Poznan
Medical University. On admission, the woman weighed
40 kg/163 cm (BMI 17). Laboratory examinations sho-
wed only slightly elevated liver enzyme levels. A com-
puted tomography (CT) of the abdomen revealed an
enlarged liver with numerous compact and cystic le-
sions, metastatic in nature, as well as a slightly enlar-
ged spleen and enlarged periaortal lymphatic nodules.
The remaining abdominal organs in CT presented no
change. Chest X-rays were negative for metastatic di-
sease. In order to interpret the lesions in the liver an
ultrasonography-guided fine-needle aspiration biopsy
was performed. Cytological and immunohistochemical
staining revealed: positive chromogranin (Fig. 1), posi-
tive synaptophysin (Fig. 2), and proliferation index ki
67 positive only in a few cell nuclei < 2% (Fig. 3). The
following diagnosis was made: metastases of a neuro-
endocrine cancer belonging to the group I B according
to the 2000 WHO histopathological classification of NET.
Endoscopic examinations, including gastroscopy
and colonoscopy, were performed to find the primary
neoplastic focus. No abnormalities justifying the patho-
logical changes in the liver were found. The patient
underwent also a gynaecological examination with no
pathological changes found. The echocardiography did
not reveal any typical changes for a carcinoid syndro-
me. The biochemical marker evaluation revealed: ele-
vated chromogranin A serum concentration 604 ng/ml
(N: 20–98 ng/ml, Cis bio International kit), high seroto-
nin serum level 1.16 ng/ml (N: 0.069–0.199 ng/ml ), and
increased 5 HIAA urine excretion > 100 mg/24 h (N: 2–
Figure 1. Cytological evaluation showing positive expression of
chromogranin A in neuroendocrine tumour cells, demonstrated
with immunohistochemical technique (objective 300 ¥)
Rycina 1. Badanie immunohistochemiczne materiału otrzymanego
z biopsji wątroby pokazujące dodatnią ekspresję chromograniny A
(300 ¥)
Figure 2. Cytological evaluation showing positive expression of
synaptophysin in neuroendocrine tumour cells, demonstrated with
immunohistochemical technique (objective 300 ¥)
Rycina 2. Badanie immunohistochemiczne materiału otrzymanego
z biopsji wątroby pokazujące dodatnią ekspresję synaptofizyny
(300 ¥)
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6 mg/24 h). Clinically, the symptoms listed above persi-
sted: diarrhoea (5–6 times per day), abdominal pain, and
general weakness. As a consequence of the diagnosis
of a neuroendocrine tumour of unknown origin, a so-
matostatin receptor scintigraphy with the application
of labelled somatostatin analog 99mTc- HYNIC — TOC
was performed. The scanning showed numerous pa-
thological foci of marker accumulation in the liver pro-
jection, which corresponded to the changes revealed
by CT (Fig. 4).
In order to control the clinical symptoms presented
by the patient, a somatostatin analog therapy was initia-
ted (Sandostatin LAR 30 mg s.c./ 28 days). A decrease in
the chromogranin A level to 334 ng/ml was noted after
two shots of Sandostatin LAR, and the 5- HIAA excre-
tion in 24-hour urine showed 52.3 mg/24 h. Parallel to
this treatment, numerous tests qualifying the patient for
targeted radionuclide therapy were carried out. There-
fore, a followed-up CT of the abdomen showed, besides
the metastatic changes within the liver, a well-vasculari-
sed tumour of size 14 ¥ 23 ¥ 16 mm, bound up with the
jejunum, growing into and out of its lumen (Fig. 5).
Considering the fact that the tumour could be the
primary focus of the neuroendocrine neoplasm, the
patient was referred to the Surgery Clinic of Poznan
University. Unexpectedly, the histopathological and
immunohistochemical examination revealed a positive
cell reaction for CD 117, confirming the diagnosis of
a rare jejunal stromal tumour. The size of the tumour
(< 2 cm) and the mitotic activity (< 5 per 50 HPF [high
powered field]) suggested a low risk of aggressive be-
haviour of the stromal tumour (Fig. 6, 7).
Figure 4. Technetium 99m octreoscan demonstrating pathological tracer accumulation in numerous metastatic foci in the liver on the
anterior (A) and posterior projection (B)
Rycina 4. Scyntygrafia receptorowa całego ciała: widoczne liczne ogniska patologicznego gromadzenia znacznika w rzucie wątroby.
Zmiany widoczne w projekcji przedniej (A) i tylnej (B)
Figure 5. Abdominal CT scan image showing multiple metastatic
neuroendocrine lesions in the liver and a well-vascularized tumour
bound up with the jejunum — GIST (single arrow)
Rycina 5. Tomografia komputerowa jamy brzusznej pokazująca
liczne neuroendokrynne ogniska przerzutowe w wątrobie oraz
unaczyniony guz wyrastający z jelita cienkiego (strzałka)
A B
Figure 3. Cytological evaluation showing Expression of proliferation
marker Ki-67 in cell nucleus of neuroendocrine cancer, demonstrated
with immunohistochemical technique (Objective 300 ¥)
Rycina 3. Badanie immunohistochemiczne materiału otrzymanego
z biopsji wątroby pokazujące ekspresję Ki-67 w pojedynczych
jądrach komórkowych (300 ¥)
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UFigure 6. Histopathological evaluation showing the GIST tumour
bound up with the jejunum (H + E, 10 ¥ magnification)
Rycina 6. Badanie histopatologiczne tkanki guza stromalnego
jelita cienkiego (H + E)
Figure 7. Positive expression of CD11 in GIST cells demonstrated
with immunohistochemical technique (40 ¥ magnification)
Rycina 7. Badanie immunohistochemiczne pokazujące dodatnią
ekspresję CD117 potwierdzające rozpoznanie guza typu GIST w
obrębie jelita cienkiego
Two months later, peptide-receptor therapy was
initiated. Our patient received two doses of 90Y/ 77Lu
— DOTA-TATE (100 millicuries per dose), with a two-
month interval. The last noted chromogranin A level
was 540 ng/ml, suggesting stabilization of the disease.
Further therapy is expected.
Discussion
Developments in recent years have shed some light
on the role of growth factors like IGF-1, TGF, VEGF,
and PDGF on the regulation of differentiation, growth,
and secretion of tumour cells. Basic fibroblast growth
factor, a potent stimulant of endothelial cell growth, is
expressed in both carcinoid tumour tissue and carcino-
id cell line [8].Vascular endothelial growth factor (VEGF)
expression has been demonstrated in both gastrointe-
stinal and pulmonary carcinoids [9]. Expression of TGF-
alpha, TGF-b, and epidermal growth factor receptor
(EGFR) has been found on carcinoid tumours [8]. On
the other hand, to understand the mechanism of tumo-
ur genesis, progression, and differentiation of GISTs,
Nakayama et al. investigated the immunohistochemi-
cal expression of vascular endothelial growth factor
(VEGF) and its receptor VEGFR-1 and 2 in 33 specimens
of GISTs. The authors found positive expression of
VEGF in the cytoplasm of the GIST (79%), and expres-
sion of VEGFR-1 (70%) and VEGFR-2 (91%) in the mem-
brane and cytoplasm of GIST [10].
Both neuroendocrine tumours with GISTs may be
seen in neurofibromatosis type I [11, 12]. Our patient
had no familial history or clinical manifestation, neither
of neurofibromatosis nor of multiple endocrine neopla-
sia. The neuroendocrine neoplasm was disseminated
and was of unknown primary origin; however, symp-
toms presented by the patient (abdominal pain, diarr-
hoea), elevated biochemical marker (CGA, 5 HIAA), and
negative result of chest X-ray, gastroscopy, and colo-
noscopy suggest a small bowel localization of the pri-
mary focus. At this advanced disease stage, a jejunal,
highly vascularised tumour appeared. For us, this tu-
mour was strongly suspected to be the primary origin
of the neuroendocrine metastases, and for that reason,
before starting the peptide-receptors therapy, the pa-
tient was sent to the operating room. Unexpectedly, the
histopathological report revealed GIST, a completely
different cancer, which required another diagnostic and
therapeutic approach.
We conclude that in patients with metastatic disse-
minated neuroendocrine neoplasms of unknown ori-
gin, tumours suspected to be the primary focus should
be removed because they could turn out to be a second
completely different cancer, which is of particular im-
portance in the prognosis and therapeutic approach to
the management of both neoplasms. Additionally, our
case shows that in disseminated, well-differentiated
tumours with positive SRS neuroendocrine, targeted
peptide-receptors therapy should be considered.
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